Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

e to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400

                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (unaudited)

                                                  Three Months Ended
                                                        March 31,
                                                  2009            2008
    Operating expenses:
      Research and development                $6,139,342    $10,478,047
      Marketing                                  536,115        583,702
      General and administrative               2,811,747      2,667,038
      Other                                      650,786         28,257
        Total operating expenses              10,137,990     13,757,044

    Loss from operations                     (10,137,990)   (13,757,044)

    Other (expense) income, net                 (299,373)        40,129

    Net loss                                $(10,437,363)  $(13,716,915)

    Basic and diluted net loss per share(1)       $(0.24)        $(0.42)

    Shares used to compute basic and
    diluted net loss per share(1)             43,831,889     32,921,093

    (1) As a result of the issuance of 12,039,794 shares of common stock
        pursuant to a private placement in the first quarter of 2009 and
        9,240,307 shares of common stock pursuant to an effective shelf
        registration in the first qu
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... The Latin American hardware encryption display market report defines ... and forecast of revenue. This market was valued at ... $2,366.8 million by 2018, at a CAGR of 70.3% ... of the Latin American hardware encryption market report to ... also provides a glimpse of the segmentation of the ...
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, ... Company"),a Xianyang-based developer, manufacturer and supplier of pharmaceutical,products ... and conditions,today announced that management will hold a ... 10:30 a.m. EDT on Friday, August 14, 2009. ...
... from Roman mythology when they named a unique class ... usually depicted as having two faces looking in opposite ... the tantalizing possibilities of these particles for their potential ... devices. However, realizing these applications requires precise control over ...
... SHANGHAI, Aug. 11 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... outsourcing company serving the,pharmaceutical, biotechnology, and medical device industries, ... its financial results for,second-quarter 2009. , ... 2009 Highlights, -- Net revenues totaled ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 2Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 3Capping a two-faced particle gives duke engineers complete control 2WuXi PharmaTech Announces Second-Quarter 2009 Results 2WuXi PharmaTech Announces Second-Quarter 2009 Results 3WuXi PharmaTech Announces Second-Quarter 2009 Results 4WuXi PharmaTech Announces Second-Quarter 2009 Results 5WuXi PharmaTech Announces Second-Quarter 2009 Results 6WuXi PharmaTech Announces Second-Quarter 2009 Results 7WuXi PharmaTech Announces Second-Quarter 2009 Results 8WuXi PharmaTech Announces Second-Quarter 2009 Results 9WuXi PharmaTech Announces Second-Quarter 2009 Results 10WuXi PharmaTech Announces Second-Quarter 2009 Results 11WuXi PharmaTech Announces Second-Quarter 2009 Results 12WuXi PharmaTech Announces Second-Quarter 2009 Results 13WuXi PharmaTech Announces Second-Quarter 2009 Results 14WuXi PharmaTech Announces Second-Quarter 2009 Results 15WuXi PharmaTech Announces Second-Quarter 2009 Results 16
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Translational Genomics Research Institute (TGen) is presenting two key studies, ... Cancer, July 3-7 in Amsterdam. One study, presented July ... effectiveness of the most common combination chemotherapy given to patients ... today, July 7, suggests that combination drug therapy may be ...
... boy bands of Americathere,s a new group in town. ... San Diego, California, entered The Christopher Columbus Awards Competition, ... challenges middle-school students to identify a community problem and ... from the popular group the Backstreet Boys, the students ...
... Researchers at the John Theurer Cancer Center recently published a ... stem cell transplants. Scott Rowley, M.D., Chief, Blood & Marrow ... Hackensack University Medical Center contributed to the study which was ... was published in the Journal of Consulting and Clinical ...
Cached Biology News:TGen presents lung cancer studies at Amsterdam conference 2Middle-school students educate community on proper computer posture 2John Theurer Cancer Center BMT researchers highlight the importance of social support 2
... member of the caudal-related homeobox family, is ... proliferation and differentiation in intestinal epithelial cells. ... cells towards the phenotype of differentiated villus ... of the phenotype. Clone CDX2-88 reacts with ...
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Biology Products: